The use of cell free DNA in the diagnosis of HCC

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide and is associated with high mortality. The currently used methods for diagnosing HCC, including imaging modalities and liver biopsy, detect tumors at a relatively advanced stage or are invasive. Non-invasive biomarkers are urgently needed to facilitate screening and early diagnosis of HCC, as well as treatment monitoring and detection of tumor recurrence. Liquid biopsy, the analysis of blood or other body fluids to obtain genetic and epigenetic information, has historically been applied to other types of cancer including breast and prostate cancer. Over the past few decades, liquid biopsy analysis has shed significant insights on genetic and epigenetic aberrations in HCC detectable in peripheral blood. Aberrations in nucleic acids found circulating freely in body fluids or contained within extracellular vesicles such as exosomes or microvesicles show potential clinical utility as non-invasive biomarkers. In this review, we present available literature on cell-free nucleic acids in the diagnosis of HCC.

Keywords

Hepatocellular carcinoma / liquid biopsy / cell free nucleic acid / cell free DNA / exosomes / microvesicles / biomarkers

References

[1] Banini BA.Hepatocellular carcinoma. Complications of Cirrhosis: Evaluation and management.2015;Springer International Publishing1-370

[2] Altekruse SF,Reichman ME.Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005..J Clin Oncol2009;27:1485-91 PMCID:PMC2668555

[3] Punnoose EA,Spoerke JM,Pandita A.Molecular biomarker analyses using circulating tumor cells..PLoS One2010;5:e12517 PMCID:PMC2935889

[4] Crowley E,Loupakis F.Liquid biopsy: monitoring cancer-genetics in the blood..Nat Rev Clin Oncol2013;10:472-84

[5] Hirai H.Lectin affinity electrophoresis of alpha-fetoprotein. Increased specificity and sensitivity as a marker of hepatocellular carcinoma..J Chromatogr1992;604:91-4

[6] Bruix J.Management of hepatocellular carcinoma: an update..Hepatology2011;53:1020-2 PMCID:PMC3084991

[7] Marrero JA,Wang Y,Befeler AS.Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma..Gastroenterology2009;137:110-8 PMCID:PMC2704256

[8] Lok AS,Everhart JE,Hoefs JC.Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma..Gastroenterology2010;138:493-502 PMCID:PMC2819612

[9] Farinati F,De Giorgio M,Cantarini M.Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?.Am J Gastroenterol2006;101:524-32

[10] Mandel P.Les acides nucléiques du plasma sanguin chez l’homme..C R Seances Soc Biol Fil1948;142:241-3

[11] Leon SA,Sklaroff DM.Free DNA in the serum of cancer patients and the effect of therapy..Cancer Res1977;37:646-50

[12] Vasioukhin V,Maurice P,Lederrey C.Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia..Br J Haematol1994;86:774-9

[13] Cachia PG,Thompson PW,Masters G.Non-dysplastic myelodysplasia?.Leukemia1994;8:677-81

[14] Sorenson GD,Valone FH,Bzik DJ.Soluble normal and mutated DNA sequences from single-copy genes in human blood..Cancer Epidemiol Biomarkers Prev1994;3:67-71

[15] Matsumura M,Niwa Y,Ogura K.Presence of alpha-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinoma..J Hepatol1999;31:332-9

[16] Cillo U,Vitale A,Basso D.Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma..Clin Chim Acta2004;347:129-38

[17] Jeng KS,Tsai YC.Does the presence of circulating hepatocellular carcinoma cells indicate a risk of recurrence after resection?.Am J Gastroenterol2004;99:1503-9

[18] Xu H,Chen Y.Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma..Clin Chem Lab Med2018;56:479-84

[19] Mitchell PS,Kroh EM,Wyman SK.Circulating microRNAs as stable blood-based markers for cancer detection..Proc Natl Acad Sci U S A2008;105:10513-8 PMCID:PMC2492472

[20] Zheng Q,Yu H,He X.Tumor-specific transcripts are frequently expressed in hepatocellular carcinoma with clinical implication and potential function..Hepatology2019;

[21] Koduru SV,Kawasawa YI,Gusani NJ.Non-coding RNAs in various stages of liver disease leading to hepatocellular carcinoma: differential expression of miRNAs, piRNAs, lncRNAs, circRNAs, and sno/mt-RNAs..Sci Rep2018;8:7967 PMCID:PMC5964116

[22] Tian XP,Jin XH,Wang FW.Acidic microenvironment up-regulates exosomal miR-21 and miR-10b in early-stage hepatocellular carcinoma to promote cancer cell proliferation and metastasis..Theranostics2019;9:1965-79 PMCID:PMC6485281

[23] Koberle V,Pleli T,Imelmann E.Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma..Eur J Cancer2013;49:3442-9

[24] Qu KZ,Li H,Albitar M.Circulating microRNAs as biomarkers for hepatocellular carcinoma..J Clin Gastroenterol2011;45:355-60

[25] Ge W,Li QG,Zhang CY.Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances..Clin Lab2014;60:427-34

[26] El-Abd NE,El-Sheikh SM.Circulating miRNA-122, miRNA-199a, and miRNA-16 as biomarkers for early detection of hepatocellular carcinoma in egyptian patients with chronic hepatitis C virus infection..Mol Diagn Ther2015;19:213-20

[27] Qi P,Wang H,Chen YF.Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection..PLoS One2011;6:e28486 PMCID:PMC3234251

[28] Liu M,Wang L,Zhou C.Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival..PLoS One2014;9:e109347 PMCID:PMC4183700

[29] Zekri AN,El-Desouky ED,Lotfy MM.Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection..Tumour Biol2016;37:12273-86

[30] Mirzaei HR,Mohammadi M,Salehi H.Circulating microRNAs in hepatocellular carcinoma: potential diagnostic and prognostic biomarkers..Curr Pharm Des2016;22:5257-69

[31] Forshew T,Parkinson C,Tsui DW.Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA..Sci Transl Med2012;4:136ra68

[32] Newman AM,To J,Eclov NC.An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage..Nat Med2014;20:548-54 PMCID:PMC4016134

[33] Chen H,Zheng HQ,Jin XM.Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma..Pathology2012;44:318-24

[34] Huang Z,Hu Y,Zhou X.Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma..Pathol Oncol Res2012;18:271-6

[35] Chan KC,Zheng YW,Sun H.Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing..Clin Chem2013;59:211-24

[36] Jiang P,Chan KC,Wong J.Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients..Proc Natl Acad Sci U S A2015;112:E1317-25 PMCID:PMC4372002

[37] Wong IH,Yeo W,Johnson PJ.Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients..Clin Cancer Res2000;6:3516-21

[38] Ren N,Tu H,Zhang BH.The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma..J Cancer Res Clin Oncol2006;132:399-407

[39] Iizuka N,Moribe T,Miura T.Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma..Anticancer Res2006;26:4713-9

[40] Piciocchi M,Vitale A,Giacomin A.Circulating free DNA in the progression of liver damage to hepatocellular carcinoma..Hepatol Int2013;7:1050-7

[41] Yan L,Zhou J,Zhang H.Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma..Int J Infect Dis2018;67:92-7

[42] Szymanska K,Cui Y,Turner PC.TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China..Cancer Epidemiol Biomarkers Prev2009;18:1638-43

[43] Bettegowda C,Leary RJ,Wang Y.Detection of circulating tumor DNA in early- and late-stage human malignancies..Sci Transl Med2014;6:224ra24 PMCID:PMC4017867

[44] Yu L,Han C,Zhu G.XRCC1 rs25487 genetic variant and TP53 mutation at codon 249 predict clinical outcomes of hepatitis B virus-related hepatocellular carcinoma after hepatectomy: a cohort study for 10 years’ follow up..Hepatol Res2016;46:765-74

[45] Cai ZX,Zeng YY,Lin MJ.Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma..Int J Cancer2017;141:977-85

[46] Huang A,Zhou SL,Huang XW.Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity..J Cancer2016;7:1907-14 PMCID:PMC5039376

[47] Nault JC.Genetics of hepatocellular carcinoma: the next generation..J Hepatol2014;60:224-6

[48] Kan Z,Liu X,Barber TD.Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma..Genome Res2013;23:1422-33 PMCID:PMC3759719

[49] Fujimoto A,Abe T,Hosoda F.Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators..Nat Genet2012;44:760-4

[50] Nault JC,Pilati C,Bioulac-Sage P.High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions..Nat Commun2013;4:2218 PMCID:PMC3731665

[51] Nault JC,Di Tommaso L,Zafrani ES.Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis..Hepatology2014;60:1983-92

[52] Pinyol R,Llovet JM.TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma..J Hepatol2014;61:685-7

[53] Hann HW,Park G,Song W.Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma..Hepatoma Res2017;3:105-11 PMCID:PMC5546802

[54] Hosny G,Tayel H.Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases..Cancer Lett2008;264:201-8

[55] Kuang SY,Maneekarn N,Brodovicz K.Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand..Cancer Epidemiol Biomarkers Prev2005;14:380-4

[56] Szymanska K,Kirk GD,Taniere P.Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa..Int J Cancer2004;110:374-9

[57] Lleonart ME,Villar S,Dasgupta A.Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry..Cancer Epidemiol Biomarkers Prev2005;14:2956-62

[58] Ikeda S,Skjevik AA,Mendler M.Next-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma..Oncologist2018;23:586-93 PMCID:PMC5947459

[59] Cohen JD,Wang Y,Afsari B.Detection and localization of surgically resectable cancers with a multi-analyte blood test..Science2018;359:926-30 PMCID:PMC6080308

[60] Ono A,Yamamoto Y,Hiraga N.Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy..Cell Mol Gastroenterol Hepatol2015;1:516-34 PMCID:PMC5301414

[61] Huang A,Zhou SL,Huang XW.Plasma Circulating cell-free DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma..J Cancer2016;7:1798-803 PMCID:PMC5039362

[62] Pang JZ,Wang QQ,Sun BS.Loss of heterozygosity of plasma circulating DNA from hepatocellular carcinoma patients and its clinical significance..Zhonghua Gan Zang Bing Za Zhi2007;15:906-9

[63] Pang JZ,Ren N,Ying WD.Microsatellite alterations of circulating DNA in the plasma of patients with hepatocellular carcinoma..Zhonghua Yi Xue Za Zhi2006;86:1662-5

[64] Zhang YJ,Shen J,Tsai WY.Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA..Clin Cancer Res2007;13:2378-84

[65] Iyer P,Hung CW,Ismail K.Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients..Exp Mol Pathol2010;88:107-11 PMCID:PMC4512240

[66] Iizuka N,Sakaida I,Miura T.Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers..Clin Chim Acta2011;412:152-8

[67] Huang ZH,Hua D,Song MX.Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma..Exp Mol Pathol2011;91:702-7

[68] Sun FK,Zhao J,Gao S.Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients..Dig Dis Sci2013;58:1010-5

[69] Chang H,Li L,Sun F.Methylation of tumor associated genes in tissue and plasma samples from liver disease patients..Exp Mol Pathol2008;85:96-100

[70] Yeo W,Wong WL,Zhong S.High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma..Liver Int2005;25:266-72

[71] Borowa-Mazgaj B,Tryndyak V,Jimenez L.Gene expression and DNA methylation alterations in the glycine N-methyltransferase gene in diet-induced nonalcoholic fatty liver disease-associated carcinogenesis..Toxicol Sci2019;

[72] Tangkijvanich P,Rattanatanyong P,Mahachai V.Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma..Clin Chim Acta2007;379:127-33

[73] Mohamed NA,Amin NF,Tag-Eldin LM.Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C?.Arab J Gastroenterol2012;13:111-5

[74] Xu RH,Krawczyk M,Luo H.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma..Nat Mater2017;16:1155-61